Presentation (CTI)

OBJECTIVES: Cervical cancer remains a major public health concern in France, with approximately 3,000 new cases and 1,000 deaths annually. The national screening program invites women aged 25-29 for Pap smears (two tests one year apart, then every three years) and women aged 30-65 for high-risk HPV testing every five years. Despite this, participation remains limited at 59.5%. In comparison, the UK achieves 69% coverage through systematic invitations starting at age 25, while Turkey reaches 82% by offering free HPV testing every five years, supported by strong public outreach and centralized follow-up systems.The objective is to evaluate the economic impact of reinforcing organized cervical cancer screening to improve early detection and reduce healthcare costs.
METHODS: A health economic evaluation was conducted using literature review, internal Cerba data, Biol’AM database insights, grey literature, and medico-economic modeling to estimate the financial implications of enhanced screening strategies.
RESULTS: The target population includes 4.3 million individuals, with 3,160 new cases annually and an average age of 55. The annual cost of cervical cancer management in France is estimated at €239 million. Modeling suggests that strengthening screening could reduce incidence and mortality by 30% over ten years. In the long term, up to 90% of cervical cancer cases could be prevented through effective and widespread screening. This would generate €306 million in savings over ten years, even after accounting for screening-related expenses.
CONCLUSIONS: Enhancing follow-up, targeting non-responders, and sending periodic SMS reminders can significantly boost participation in cervical cancer screening, reduce incidence and mortality, and improve healthcare system efficiency.